3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Conditions
Prostatic Neoplasms
8
Carcinoma, Renal Cell
6
Urinary Bladder Neoplasms
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Multiple Myeloma
3
Lymphoma, Non-Hodgkin
3
Leukemia, Myeloid, Acute
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Hodgkin Disease
3
Carcinoma, Non-Small-Cell Lung
3
Wilms Tumor
2
Squamous Cell Carcinoma of Head and Neck
2
Sezary Syndrome
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Neuroblastoma
2
Neoplasms
2
Myeloproliferative Disorders
2
Mycosis Fungoides
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Follicular
2
Lymphoma
2
Leukemia, Myelomonocytic, Chronic
2
Leukemia, Myeloid, Chronic-Phase
2
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
2
Leukemia, Hairy Cell
2
Breast Neoplasms
2
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Thrombocytosis
1
Interventions
fludarabine
3
Radiotherapy
3
Cyclophosphamide
3
entinostat
2
aldesleukin
2
aflibercept
2
Trastuzumab
2
Nivolumab
2
Adoptive Transfer
2
trastuzumab deruxtecan
1
tivozanib
1
tipifarnib
1
rocakinogene sifuplasmid
1
pembrolizumab
1
oncogene protein E7, Human papillomavirus type 16
1
durvalumab
1
bintrafusp alfa protein, human
1
atezolizumab
1
Vorinostat
1
VGX-3100
1
Specimen Handling
1
Ritonavir
1
Radiation
1
Quality of Life
1
Patient Reported Outcome Measures
1
Octreotide
1
Observation
1
Molecular Diagnostic Techniques
1
Magnetic Resonance Spectroscopy
1
MEDI0457
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Vulvar Neoplasms
×
Vorinostat
×
Genitourinary
×
Clear all
NCT04357873
2025-02-19
PEVOsq
UNICANCER
Phase 2
Completed
112 enrolled